Atomoxetine

Generic Name
Atomoxetine
Brand Names
Strattera
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
83015-26-3
Unique Ingredient Identifier
ASW034S0B8
Background

Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...

Indication

Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Associated Therapies
-
globenewswire.com
·

Fennec Pharmaceuticals Strengthens Executive Leadership

Fennec Pharmaceuticals appoints Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer to strengthen its executive team and accelerate the commercialization of PEDMARK, the first therapy to reduce ototoxicity risk from cisplatin treatment in pediatric patients.
healio.com
·

The inside story of Cobenfy

The FDA's approval of Cobenfy (KarXT) marks a significant milestone in psychopharmacology as the first antipsychotic not targeting dopamine 2 receptors. The drug's journey began with xanomeline, synthesized by Novo Nordisk in the 1980s, showing promise in Alzheimer's and schizophrenia studies but shelved by Eli Lilly. Resurrected by Steven M. Paul, MD, who combined it with trospium at Karuna, the drug's approval highlights the industry's potential lapses in foresight and unnecessary delays in bringing effective treatments to market.
© Copyright 2024. All Rights Reserved by MedPath